Combination lotion for plaque psoriasisJuly 5, 2019
The US FDA has approved a topical lotion for the treatment of plaque psoriasis in adults.
The lotion is having a combination of halobetasol propionate and tazarotene. The drug will be marketed by the brand name Duobrit for the treatment plaque psoriasis, said Bausch Health.
A Phase 2 study demonstrated the lotion was consistently more effective than its individual agents and vehicle in achieving treatment success and
reducing psoriasis signs of erythema, plaque elevation, and scaling at the target lesion.
The safety and efficacy of the once-daily use of the topical application was assessed in two Phase 3 prospective, multicentre, randomized, double-blind clinical trials in subjects 18 years and older with moderate to severe plaque psoriasis.Its effectivity in children is still not known.